# COOPER COMPANIES, INC. (COO)

Informational only - not investment advice.

CIK: 0000711404
SIC: 3851 Ophthalmic Goods
SIC breadcrumb: [Manufacturing](/division/D/) > [SIC Major Group 38](/major-group/38/) > [SIC 3851 Ophthalmic Goods](/industry/3851/)
Latest 10-K filed: 2025-12-05
SEC page: https://www.sec.gov/edgar/browse/?CIK=711404
Filing source: https://www.sec.gov/Archives/edgar/data/711404/000162828025055615/coo-20251031.htm

## At a glance

FY2025 · period end 2025-10-31 · filed 2025-12-05 · accession 0001628280-25-055615 · source: https://data.sec.gov/api/xbrl/companyfacts/CIK0000711404.json

| Metric | Value | FY | Provenance |
| --- | ---: | ---: | --- |
| Revenue | 4,092,400,000 USD | 2025 | verified |
| Net income | 374,900,000 USD | 2025 | verified |
| Assets | 12,394,800,000 USD | 2025 | verified |
| Free cash flow | 433,700,000 USD | 2025 | computed |
| Net margin | 9.16% | 2025 | computed |
| Operating margin | 16.69% | 2025 | computed |
| Revenue YoY | +5.06% | 2025 | computed |
| ROE | 4.55% | 2025 | computed |

Computed values are grepcent-computed from the verified facts above and may differ from ratios the company itself reports. Free cash flow = operating cash flow − capital expenditures. Net margin = net income ÷ revenue. Operating margin = operating income ÷ revenue. Revenue YoY = FY2025 revenue ÷ FY2024 revenue − 1 (consecutive fiscal years only). ROE = net income ÷ period-end stockholders' equity.

No market price, no rating, no forecast on this site. Not investment advice.

### Peer percentile fingerprint

| Ratio | COO | Peer median | Percentile | N |
| --- | ---: | ---: | ---: | ---: |
| Net margin | 9.2% | 3.1% | 64 | 148 |
| Operating margin | 16.7% | 6.4% | 75 | 145 |
| Revenue growth | 5.1% | 8.3% | 36 | 153 |
| FCF margin | 10.6% | 7.4% | 56 | 152 |
| ROE | 4.6% | 2.4% | 53 | 145 |
| ROA | 3.0% | 1.1% | 56 | 154 |
| Liabilities / equity | 0.50 | 0.82 | 33 | 150 |
| Current ratio | 1.89 | 2.81 | 29 | 153 |

Percentile = share of the N covered peers reporting that ratio whose value is lower (ties counted half); computed among grepcent-covered companies in SIC major-group 38 SIC Major Group 38, not the whole market. A higher percentile means a higher value of the ratio, not a better company. Ratios with fewer than 8 reporting peers are omitted. Latest reported values per company; fiscal periods may differ. Descriptive arithmetic - not a score, rating, or ranking.

## Selected Fundamentals
| Metric | Value | Unit | FY | Filed |
| --- | ---: | --- | ---: | --- |
| Revenue | 4092400000 | USD | 2025 | 2025-12-05 |
| Net income | 374900000 | USD | 2025 | 2025-12-05 |
| Assets | 12394800000 | USD | 2025 | 2025-12-05 |

## Financials

Annual standardized facts from SEC companyfacts as of latest extracted filing date 2025-12-05. Source: https://data.sec.gov/api/xbrl/companyfacts/CIK0000711404.json. Derived margins, ratios, and free cash flow are computed from the extracted annual SEC facts.

| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue |  | 2,139,000,000 | 2,532,800,000 | 2,653,400,000 | 2,430,900,000 |  | 3,308,400,000 | 3,593,200,000 | 3,895,400,000 | 4,092,400,000 |
| Net income | 273,900,000 | 372,900,000 | 139,900,000 | 466,700,000 | 238,400,000 | 2,944,700,000 | 385,800,000 | 294,200,000 | 392,300,000 | 374,900,000 |
| Operating income | 324,100,000 | 429,100,000 | 403,100,000 | 546,700,000 | 311,800,000 | 505,800,000 | 507,600,000 | 533,100,000 | 705,700,000 | 682,900,000 |
| Gross profit | 1,173,100,000 | 1,365,800,000 | 1,632,300,000 | 1,756,800,000 | 1,534,800,000 | 1,955,800,000 | 2,139,600,000 | 2,357,900,000 | 2,595,700,000 | 2,682,100,000 |
| Diluted EPS | 5.59 | 7.52 | 2.81 | 9.33 | 4.81 | 59.16 | 1.94 | 1.48 | 1.96 | 1.87 |
| Operating cash flow | 509,600,000 | 593,600,000 | 668,900,000 | 713,200,000 | 486,600,000 | 738,600,000 | 692,400,000 | 607,500,000 | 709,300,000 | 796,100,000 |
| Capital expenditures | 152,600,000 | 127,200,000 | 193,600,000 | 292,100,000 | 310,400,000 | 214,400,000 | 242,000,000 | 392,500,000 | 421,200,000 | 362,400,000 |
| Dividends paid | 2,900,000 | 2,900,000 | 2,900,000 | 3,000,000 | 3,000,000 | 3,000,000 | 3,000,000 | 3,000,000 | 0.00 | 0.00 |
| Share buybacks | 0.00 | 55,000,000 | 0.00 | 156,100,000 | 47,800,000 | 24,800,000 | 78,500,000 | 0.00 | 0.00 | 290,100,000 |
| Assets | 4,478,600,000 | 4,858,700,000 | 6,112,800,000 | 6,274,500,000 | 6,737,500,000 | 9,606,200,000 | 11,492,300,000 | 11,658,900,000 | 12,315,200,000 | 12,394,800,000 |
| Liabilities | 1,782,700,000 | 1,682,900,000 | 2,805,000,000 | 2,645,900,000 | 2,912,700,000 | 2,664,200,000 | 4,317,600,000 | 4,107,900,000 | 4,231,600,000 | 4,155,700,000 |
| Stockholders' equity | 2,695,800,000 | 3,175,700,000 | 3,307,600,000 | 3,628,400,000 | 3,824,600,000 | 6,941,800,000 | 7,174,500,000 | 7,550,800,000 | 8,083,400,000 | 8,238,900,000 |
| Cash and cash equivalents | 100,800,000 | 88,800,000 | 77,700,000 | 89,000,000 | 115,900,000 | 95,900,000 | 138,200,000 | 120,800,000 | 107,600,000 | 110,600,000 |
| Free cash flow | 357,000,000 | 466,400,000 | 475,300,000 | 421,100,000 | 176,200,000 | 524,200,000 | 450,400,000 | 215,000,000 | 288,100,000 | 433,700,000 |

### Ratios

ROE and ROA use period-end equity/assets. Liabilities / equity uses total liabilities divided by stockholders' equity. Current ratio uses current assets divided by current liabilities when both are reported.

| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Net margin |  | 17.43% | 5.52% | 17.59% | 9.81% |  | 11.66% | 8.19% | 10.07% | 9.16% |
| Operating margin |  | 20.06% | 15.92% | 20.60% | 12.83% |  | 15.34% | 14.84% | 18.12% | 16.69% |
| Return on equity | 10.16% | 11.74% | 4.23% | 12.86% | 6.23% | 42.42% | 5.38% | 3.90% | 4.85% | 4.55% |
| Return on assets | 6.12% | 7.67% | 2.29% | 7.44% | 3.54% | 30.65% | 3.36% | 2.52% | 3.19% | 3.02% |
| Liabilities / equity | 0.66 | 0.53 | 0.85 | 0.73 | 0.76 | 0.38 | 0.60 | 0.54 | 0.52 | 0.50 |
| Current ratio | 1.73 | 2.41 | 2.03 | 1.05 | 1.27 | 2.00 | 1.20 | 1.76 | 1.91 | 1.89 |

## As-reported value updates

No tracked differences above grepcent's stated thresholds and capped precision rule were found between the earliest XBRL-filed value and the value currently on file for the standardized annual metrics grepcent tracks.


## Quarterly

Quarterly standardized facts from SEC companyfacts as of latest extracted filing date 2026-06-05. Source: https://data.sec.gov/api/xbrl/companyfacts/CIK0000711404.json.

Flow metrics use discrete quarter-length periods from 10-Q/10-Q/A filings. Q4 revenue and net income are derived only when annual FY and nine-month YTD facts exist for the same fiscal year; derived Q4 values are labeled. EPS Q4 is not derived.

| Quarter | End date | Revenue | Net income | Diluted EPS | Method |
| --- | --- | ---: | ---: | ---: | --- |
| 2022-Q3 | 2022-07-31 |  |  | 1.98 | reported discrete quarter |
| 2023-Q1 | 2023-01-31 |  |  | 1.70 | reported discrete quarter |
| 2023-Q2 | 2023-04-30 |  |  | 0.80 | reported discrete quarter |
| 2023-Q3 | 2023-04-30 |  | 39,800,000 |  | reported discrete quarter |
| 2023-Q3 | 2023-07-31 | 930,200,000 |  | 1.71 | reported discrete quarter |
| 2023-Q4 | 2023-10-31 | 927,100,000 | 84,500,000 |  | derived Q4 = FY annual - nine-month YTD |
| 2024-Q1 | 2024-01-31 | 931,600,000 | 81,200,000 | 0.41 | reported discrete quarter |
| 2024-Q2 | 2024-01-31 |  | 81,200,000 |  | reported discrete quarter |
| 2024-Q2 | 2024-04-30 | 942,600,000 |  | 0.44 | reported discrete quarter |
| 2024-Q3 | 2024-04-30 |  | 88,900,000 |  | reported discrete quarter |
| 2024-Q3 | 2024-07-31 | 1,002,800,000 |  | 0.52 | reported discrete quarter |
| 2024-Q4 | 2024-10-31 | 1,018,400,000 | 117,500,000 |  | derived Q4 = FY annual - nine-month YTD |
| 2025-Q1 | 2025-01-31 | 964,700,000 | 104,300,000 | 0.52 | reported discrete quarter |
| 2025-Q2 | 2025-01-31 |  | 104,300,000 |  | reported discrete quarter |
| 2025-Q2 | 2025-04-30 | 1,002,300,000 |  | 0.44 | reported discrete quarter |
| 2025-Q3 | 2025-04-30 |  | 87,700,000 |  | reported discrete quarter |
| 2025-Q3 | 2025-07-31 | 1,060,300,000 |  | 0.49 | reported discrete quarter |
| 2025-Q4 | 2025-10-31 | 1,065,100,000 | 84,600,000 |  | derived Q4 = FY annual - nine-month YTD |
| 2026-Q1 | 2026-01-31 | 1,024,100,000 | 130,800,000 | 0.66 | reported discrete quarter |
| 2026-Q2 | 2026-01-31 |  | 130,800,000 |  | reported discrete quarter |
| 2026-Q2 | 2026-04-30 | 1,081,500,000 |  | -0.40 | reported discrete quarter |

## Filed narrative (10-K & 10-Q)

## Business

Verbatim Item 1 Business section from COO's latest 10-K: [/company/COO/business/](/company/COO/business/).

## Risk Factors

Verbatim Item 1A Risk Factors from COO's latest 10-K: [/company/COO/risk-factors/](/company/COO/risk-factors/).

## Latest quarter (10-Q)

Latest 10-Q source: https://www.sec.gov/Archives/edgar/data/711404/000162828026041305/coo-20260430.htm

Extracted structurally from real Item 2 body heading to real Item 3/4 boundary.
Confidence: high
Filing date: 2026-06-05
Report date: 2026-04-30

Item 2. Management’s Discussion and Analysis of Financial Condition

and Results of Operations

Note numbers refer to “Notes to Consolidated Condensed Financial Statements” in Item 1. Unaudited Financial Statements.

Forward-Looking Statements

This Quarterly Report on Form 10-Q contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These include statements relating to plans, prospects, goals, strategies, future actions, events or performance and other statements which are other than statements of historical fact, including: statements regarding the expected impact of global macroeconomic conditions, and statements regarding acquisitions (including the acquired companies' financial position, market position, product development and business strategy, expected cost synergies, expected timing and benefits of the transaction, difficulties in integrating entities or operations, as well as estimates of our and the acquired entities' future expenses, sales and earnings per share) that are forward-looking. In addition, all statements regarding anticipated growth in our net sales, anticipated effects of any product recalls, anticipated market conditions, planned product launches, restructuring or business transition expectations, regulatory plans, and expected results of operations and integration of any acquisition are forward-looking. To identify these statements, look for words like “believes,” “outlook,” “probable,” “expects,” “may,” “will,” “should,” “could,” “seeks,” “intends,” “plans,” “estimates” or “anticipates” and similar words or phrases. Forward-looking statements necessarily depend on assumptions, data or methods that may be incorrect or imprecise and are subject to risks and uncertainties. Among the factors that could cause our actual results and future actions to differ materially from those described in forward-looking statements are:

•Adverse changes in the global or regional general business, political and economic conditions, including the impact of continuing uncertainty and instability of certain countries, man-made or natural disasters and pandemic conditions, that could adversely affect our global markets, and the potential adverse economic impact and related uncertainty caused by these items.

•The impact of international conflicts, including the ongoing conflict in the Middle East, and the global response to international conflicts on the global and local economy, financial markets, energy markets, currency rates and our ability to supply product to, or through, or around, affected countries.

•Our substantial and expanding international operations and the challenges of managing an organization spread throughout multiple countries and complying with a variety of legal, compliance and regulatory requirements.

•The actual imposition or threats of tariffs, customs duties and fees by the U.S. government and other nations in response and other retaliatory actions, such as trade protection measures, import or export licensing requirements, new or different customs duties, trade embargoes and sanctions and other trade barriers, as well as the impact of the Company’s efforts to mitigate the effects of such tariffs or similar measures.

•Foreign currency exchange rate and interest rate fluctuations including the risk of fluctuations in the value of foreign currencies or interest rates that would decrease our net sales and earnings.

•Our existing and future variable rate indebtedness and associated interest expense is impacted by rate increases, which could adversely affect our financial health or limit our ability to borrow additional funds.

•Changes in tax laws, examinations by tax authorities, and changes in our geographic composition of income.

•Acquisition-related adverse effects including the failure to successfully achieve the anticipated net sales, margins and earnings benefits of acquisitions, integration delays or costs and the requirement to record significant adjustments to the preliminary fair value of assets acquired and liabilities assumed within the measurement period, required regulatory approvals for an acquisition not being obtained or being delayed or subject to conditions that are not anticipated, adverse impacts of changes to accounting controls and reporting procedures, contingent liabilities or indemnification obligations, increased leverage and lack of access to available financing (including financing for the acquisition or refinancing of debt owed by us on a timely basis and on reasonable terms).

•Compliance costs and potential liability in connection with U.S. and foreign laws and health care regulations pertaining to privacy and security of personal information, such as the Health Insurance Portability and Accountability Act of 1996 and the California Consumer Privacy Act in the U.S. and the General Data Protection Regulation requirements in Europe, including but not limited to those resulting from data security breaches.

•A major disruption in the operations of our manufacturing, accounting and financial reporting, research and development, distribution facilities or raw material supply chain due to challenges associated with integration of acquisitions, man-made or natural disasters, pandemic conditions, cybersecurity incidents or other causes.

•A major disruption in the operations of our manufacturing, accounting and financial reporting, research and development or distribution facilities due to the failure to perform by third-party vendors, including cloud computing providers or other technological problems, including any related to our information systems maintenance, enhancements or new system deployments, integrations or upgrades.

•A successful cybersecurity attack which could interrupt or disrupt our information technology systems, or those of our third-party service providers, or cause the loss of confidential or protected data.

18

THE COOPER COMPANIES, INC. AND SUBSIDIARIES

Item 2. Management’s Discussion and Analysis of Financial Condition

and Results of Operations

•Market consolidation of large customers globally through mergers or acquisitions resulting in a larger proportion or concentration of our business being derived from fewer customers.

•Disruptions in supplies of raw materials, particularly components used to manufacture our silicone hydrogel lenses.

•New U.S. and foreign government laws and regulations, and changes in existing laws, regulations and enforcement guidance, which affect areas of our operations including, but not limited to, those affecting the health care industry, including the contact lens industry specifically and the medical device or pharmaceutical industries generally, including but not limited to the EU Medical Devices Regulation (MDR) and the EU In Vitro Diagnostic Medical Devices Regulation.

•Legal costs, insurance expenses, settlement costs and the risk of an adverse decision, prohibitive injunction or settlement related to product liability, patent infringement, contractual disputes, or other litigation.

•Limitations on sales following product introductions due to poor market acceptance.

•New competitors, product innovations or technologies, including but not limited to, technological advances by competitors, new products and patents attained by competitors, and competitors' expansion through acquisitions.

•Reduced sales, loss of customers, reputational harm and costs and expenses, including from claims and litigation related to product recalls and warning letters.

•Failure to receive, or delays in receiving, regulatory approvals or certifications for products.

•Failure of our customers and end users to obtain adequate coverage and reimbursement from third-party payers for our products and services.

•The requirement to provide for a significant liability or to write off, or accelerate depreciation on, a significant asset, including goodwill, other intangible assets and idle manufacturing facilities and equipment.

•The success of our research and development activities and other start-up projects.

•Dilution to earnings per share from acquisitions or issuing stock.

•Impact and costs incurred from changes in accounting standards and policies.

•Risks related to environmental laws and requirements applicable to our facilities, products or manufacturing processes, including evolving regulations regarding the use of hazardous substances or chemicals in our products.

•Risks related to environmental, social and corporate governance issues, including those related to regulatory and disclosure requirements, climate change and sustainability.

•Other events described in our United States Securities and Exchange Commission filings, including the “Business” and “Risk Factors” sections in our Annual Report on Form 10-K for the fiscal year ended October 31, 2025, as such Risk Factors may be updated in quarterly filings including updates made in this filing.

We caution investors that forward-looking statements reflect our analysis only on their stated date. We disclaim any obligation to update or revise them except as required by law.

19

THE COOPER COMPANIES, INC. AND SUBSIDIARIES

Item 2. Management’s Discussion and Analysis of Financial Condition

and Results of Operations

Results of Operations

In this section, we discuss the results of our operations for the second quarter of fiscal 2026 ended April 30, 2026, compared with the same period of fiscal 2025. We discuss our cash flows and current financial condition under “Capital Resources and Liquidity.” Within the tables presented, percentages are calculated based on the underlying whole-dollar amounts and, therefore, may not recalculate exactly from the rounded numbers used for disclosure purposes.    

Outlook

We are optimistic about the long-term prospects for the worldwide contact lens and general health care markets, and the resilience of and growth prospects for our businesses and products. However, we face significant risks and uncertainties in our global operating environment as further described in the Part II, Item 1A "Risk Factors" herein. These risks include uncertain global and regional business, political and economic conditions, including but not limited to those associated with man-made or natural disasters, pandemic conditions, inflation, foreign exchange rate fluctuations, regulatory developments, supply chain disruptions, and escalating global trade barriers and disruptions, such as the impact of tariffs. These risks and uncertainties have adversely affected our sales, cash flow and performance in the past and could further adversely affect our future sales, cash flow and performance.

CooperVision - We compete in the worldwide contact lens market with our spherical, toric, multifocal and toric multifocal contact lenses offered in materials like silicone hydrogel Aquaform technology. We believe that there will be lower contact lens wearer dropout rates as technology improves and enhances the wearing experience through a combination of improved designs and materials and the growth of preferred modalities such as single-use and monthly wearing options. CooperVision also competes in the myopia management and specialty eye care contact lens markets with myopia management contact lenses using its ActivControl technology and with products such as orthokeratology (ortho-k) and scleral lenses. CooperVision has U.S. Food and Drug Administration (FDA) approval for its MiSight 1 day lens, which is the first and only FDA-approved product indicated to slow the progression of myopia in children with treatment initiated between the ages of 8-12. Further, CooperVision received Chinese National Medical Products Administration approval for use of the MiSight 1 day lens in China and received Japanese Ministry of Health, Labour and Welfare approval for use of the MiSi

[Excerpt truncated for page length; source filing is linked above.]

## Latest 10-K MD&A (excerpt)

Latest 10-K Item 7 source: https://www.sec.gov/Archives/edgar/data/711404/000162828025055615/coo-20251031.htm
Complete FY 2025 MD&A: /company/COO/mda/fy2025/

Extracted structurally from real Item 7 body heading to real Item 7A/8 boundary.
Confidence: high
Filing date: 2025-12-05
Report date: 2025-10-31

Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations.

Note numbers refer to “Notes to Consolidated Financial Statements” in Item 8. Financial Statements and Supplementary Data.

Results of Operations

In this section, we discuss the results of our operations for fiscal 2025 compared with fiscal 2024. We discuss our cash flows and current financial condition under “Capital Resources and Liquidity.” For a discussion related to fiscal 2024 compared with fiscal 2023, please refer to Item 7 of Part II, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the year ended October 31, 2024, which was filed with the SEC on December 6, 2024, and is available on the SEC's website at www.sec.gov and our Investor Relations website at investor.coopercos.com.

Within the tables presented, percentages are calculated based on the underlying whole-dollar amounts and, therefore, may not recalculate exactly from the rounded numbers used for disclosure purposes.

Outlook

We are optimistic about the long-term prospects for the worldwide contact lens and general health care markets, and the resilience of and growth prospects for our businesses and products. However, we face significant risks and uncertainties in our global operating environment as further described in the “Risk Factors” section in Part I, Item 1A of this filing. These risks include uncertain global and regional business, political and economic conditions, including but not limited to those associated with man-made or natural disasters, pandemic conditions, inflation, foreign exchange rate fluctuations, regulatory developments, supply chain disruptions, and escalating global trade barriers and disruptions, such as the impact of tariffs. These risks and uncertainties have adversely affected our sales, cash flow and performance in the past and could further adversely affect our future sales, cash flow and performance.

CooperVision - We compete in the worldwide contact lens market with our spherical, toric, multifocal and toric multifocal contact lenses offered in materials like silicone hydrogel Aquaform technology. We believe that there will be lower contact lens wearer dropout rates as technology improves and enhances the wearing experience through a combination of improved designs and materials and the growth of preferred modalities such as single-use and monthly wearing options. CooperVision also competes in the myopia management and specialty eye care contact lens markets with myopia management contact lenses using its ActivControl technology and with products such as orthokeratology (ortho-k) and scleral lenses. CooperVision has FDA approval for its MiSight 1 day lens, which is the first and only FDA-approved product indicated to slow the progression of myopia in children with treatment initiated between the ages of 8-12. Further, CooperVision received Chinese NMPA approval for use of the MiSight 1 day lens in China and received MHLW approval for use of the MiSight 1 day lens in Japan. CooperVision is focused on greater worldwide market penetration using recently introduced products, and we continue to expand our presence in existing and emerging markets, including through acquisitions.

Our ability to compete successfully with a full range of silicone hydrogel products is an important factor to achieving our desired future levels of sales growth and profitability. CooperVision manufactures and markets a wide variety of silicone hydrogel contact lenses. Our single-use silicone hydrogel product franchises, clariti, MyDay and MyDay Energys remain a focus as we expect increasing demand for these products, as well as future single-use products, as the global contact lens market continues to shift to this modality. Outside of single-use, the Biofinity and Avaira Vitality product families comprise our focus in the FRP, or frequent replacement product, market which encompasses the monthly and two-week modalities. Included in this segment are unique products such as Biofinity Energys, which helps individuals with digital eye fatigue.

CooperSurgical - Our CooperSurgical business competes in the fertility and women's health care market through its diversified portfolio of products and services, including fertility products and services, medical devices, cryostorage (such as cord blood and cord tissue storage) and contraception. CooperSurgical has established its market presence and distribution system by developing products and acquiring companies, products and services that complement its business model.

Competitive factors in the segments in which CooperSurgical competes include technological and scientific advances, product quality and availability, price and customer service (including response time and effective communication of product information to physicians, consumers, fertility clinics and hospitals).

46

THE COOPER COMPANIES, INC. AND SUBSIDIARIES

Management’s Discussion and Analysis of Financial Condition and Results of Operations

We protect our products through patents and trademark registrations, both in the United States and in international markets. We monitor competitive products trademark use worldwide and, when determined appropriate, we have enforced and plan to continue to enforce and defend our patent and trademark rights. We also rely upon trade secrets, licenses, technical know-how and continuing technological innovation to develop and maintain our competitive position.

CooperVision, CooperSurgical, and other trade names, trademarks or service marks of the Company and its subsidiaries appearing in this report are the property of the Company and its subsidiaries. Trade names, trademarks and service marks of the other companies appearing in this report are the property of their respective holders.

Net Sales

CooperVision Net Sales

The contact lens market has two major product categories:

•Toric and multifocal lenses including lenses that, in addition to correcting near- and farsightedness, address more complex visual defects such as astigmatism and presbyopia by adding optical properties of cylinder and axis, which correct for irregularities in the shape of the cornea; and

•Spherical lenses, including lenses that correct near- and farsightedness uncomplicated by more complex visual defects, myopia management lenses, which slow the progression of and correct myopia in age-appropriate children, and other specialty lenses.

47

THE COOPER COMPANIES, INC. AND SUBSIDIARIES

Management’s Discussion and Analysis of Financial Condition and Results of Operations

CooperVision Net Sales by Category

[[GREPCENT_TABLE]]
[["($ in millions)","2025","","","","2024","","","","2025 vs 2024 % Change"],["Toric and multifocal","$","1,351.3","","","","","$","1,257.2","","","","","7","%"],["Sphere, other","1,392.5","","","","","1,352.2","","","","","3","%"],["","$","2,743.8","","","","","$","2,609.4","","","","","5","%"]]
[[/GREPCENT_TABLE]]

In the fiscal year ended October 31, 2025, the growth experienced across all categories was positively impacted by favorable foreign exchange rate fluctuations of approximately $16.0 million.

•Toric and multifocal grew primarily through the success of Biofinity and MyDay.

•Sphere, other grew primarily through MiSight and MyDay, offset by a decrease in legacy hydrogel products.

•"Other" products represented less than 1% of net sales in fiscal 2025 and 2024.

CooperVision Net Sales by Geography

CooperVision competes in the worldwide soft contact lens market and services in three primary regions: the Americas, EMEA and Asia Pacific.

[[GREPCENT_TABLE]]
[["($ in millions)","","2025","","2024","","2025 vs. 2024 % Change"],["Americas","","$","1,124.3","","","$","1,067.3","","","5","%"],["EMEA","","1,064.4","","","988.3","","","8","%"],["Asia Pacific","","555.1","","","553.8","","","\u2014","%"],["","","$","2,743.8","","","$","2,609.4","","","5","%"]]
[[/GREPCENT_TABLE]]

CooperVision's growth in net sales in the Americas and EMEA was primarily attributable to market gains of silicone hydrogel contact lenses. The growth in EMEA was positively impacted by favorable foreign exchange rate fluctuations. Refer to CooperVision Net Sales by Category above for further discussion.

48

THE COOPER COMPANIES, INC. AND SUBSIDIARIES

Management’s Discussion and Analysis of Financial Condition and Results of Operations

CooperSurgical Net Sales

CooperSurgical supplies the fertility and women's health care market with a diversified portfolio of products and services in two categories:

•Office and surgical offerings include products that facilitate surgical and non-surgical procedures that are commonly performed primarily by obstetricians and gynecologists in hospitals, surgical centers, and medical offices. This includes medical devices, cryostorage (such as cord blood and cord tissue storage), and contraception.

•Fertility offerings include highly specialized products and services that target the in vitro fertilization process, including diagnostics testing with a goal to make fertility treatment safer, more efficient and convenient. This includes fertility consumables and equipment, donor gamete services, and genomic services (including genetic testing).

CooperSurgical Net Sales by Category

[[GREPCENT_TABLE]]
[["($ in millions)","","2025","","2024","","","2025 vs. 2024 % Change"],["Office and surgical","","$","824.0","","","$","774.7","","","","6","%"],["Fertility","","524.6","","","511.3","","","","3","%"],["","","$","1,348.6","","","$","1,286.0","","","","5","%"]]
[[/GREPCENT_TABLE]]

In the fiscal year ended October 31, 2025, office and surgical net sales increased primarily due to increased sales of Paragard contraceptive intrauterine devices and the acquisition of obp Surgical on August 1, 2024. Fertility net sales increased primarily due to an increase in revenue from genomic services and gamete services.

Gross Margin

Consolidated gross margin decreased in fiscal 2025 to 66% compared to 67% in fiscal 2024, primarily driven by inventory and long-lived asset write-offs and severance costs related to workforce optimization initiatives.

49

THE COOPER COMPANIES, INC. AND SUBSIDIARIES

Management’s Discussion and Analysis of Financial Condition and Results of Operations

Selling, General and Administrative (SGA) Expenses

[[GREPCENT_TABLE]]
[["($ in millions)","2025","","% Net Sales","","2024","","% Net Sales","","2025 vs. 2024 % Change"],["CooperVision","$","969.3","","","35","%","","$","910.7","","","35","%","","6","%"],["CooperSurgical","568.4","","","42","%","","534.2","","","42","%","","6","%"],["Corporate","90.1","","","\u2014","","","88.8","","","\u2014","","","1","%"],["","$","1,627.8","","","40","%","","$","1,533.7","","","39","%","","6","%"]]
[[/GREPCENT_TABLE]]

CooperVision's SGA expenses increased in fiscal 2025 compared to fiscal 2024 primarily due to increased selling activities, severance costs related to workforce optimization initiatives, and long-lived asset write-offs.

CooperSurgical's SGA expenses increased in fiscal 2025 compared to fiscal 2024 primarily due to severance costs related to workforce optimization initiatives, increased selling activities, and long-lived asset write-offs.

Corporate SGA expenses increased in fiscal 2025 compared to fiscal 2024 primarily due to an increase in severance costs related to workforce optimization initiatives.

Research and Development (R&D) Expenses

[[GREPCENT_TABLE]]
[["($ in millions)","2025","","% Net Sales","","2024","","% Net Sales","","2025 vs. 2024 % Change"],["CooperVision","$","91.3","","","3","%","","$","82.9","","","3","%","","10","%"],["CooperSurgical","80.9","","","6","%","","72.2","","","6","%","","12","%"],["","$","172.2","","","4","%","","$","155.1","","","4","%","","11","%"]]
[[/GREPCENT_TABLE]]

CooperVision's R&D expenses increased in fiscal 2025 compared to fiscal 2024 primarily due to an incr

[Excerpt truncated for page length; the complete text is on the linked full-MD&A page.]

Read the full FY 2025 MD&A: /company/COO/mda/fy2025/
All MD&A years: /company/COO/mda/


## MD&A history

Prior-year 10-K MD&A spans are extracted from SEC filings with the same bounded parser used for the latest filing. Each year's full verbatim text is on its own sub-page.

- [FY 2024 MD&A](/company/COO/mda/fy2024/): filed 2024-12-06; accession 0000711404-24-000074 (https://www.sec.gov/Archives/edgar/data/711404/000071140424000074/coo-20241031.htm)
- [FY 2023 MD&A](/company/COO/mda/fy2023/): filed 2023-12-08; accession 0000711404-23-000072 (https://www.sec.gov/Archives/edgar/data/711404/000071140423000072/coo-20231031.htm)
- [FY 2022 MD&A](/company/COO/mda/fy2022/): filed 2022-12-09; accession 0000711404-22-000053 (https://www.sec.gov/Archives/edgar/data/711404/000071140422000053/coo-20221031.htm)
- [FY 2021 MD&A](/company/COO/mda/fy2021/): filed 2021-12-10; accession 0000711404-21-000038 (https://www.sec.gov/Archives/edgar/data/711404/000071140421000038/coo-20211031.htm)




## Macro cross-references

Indicators mapped to this company's SIC classification (industry 3851 Ophthalmic Goods) by grepcent's deterministic macro-sector crosswalk. A navigational mapping, not a statistical or causal claim.

- [INDPRO](/indicator/INDPRO/): Industrial Production: Total Index
- [TCU](/indicator/TCU/): Capacity Utilization: Total Index
- [PPIACO](/indicator/PPIACO/): Producer Price Index by Commodity: All Commodities
- [GDPC1](/indicator/GDPC1/): Real Gross Domestic Product
- [DGS10](/indicator/DGS10/): Market Yield on U.S. Treasury Securities at 10-Year Constant Maturity
- [FEDFUNDS](/indicator/FEDFUNDS/): Federal Funds Effective Rate
- [CES0500000003](/indicator/CES0500000003/): Average Hourly Earnings of All Employees, Total Private
- [PAYEMS](/indicator/PAYEMS/): All Employees, Total Nonfarm

Macro-to-micro threads including this sector: [Inflation (CPI / PCE / PPI)](/thread/inflation-cpi-pce-ppi/), [US labor market](/thread/us-labor-market/), [Growth & output](/thread/growth-output/), [Money & trade](/thread/money-trade/), [Government finances](/thread/government-finances/), [Sector employment](/thread/sector-employment/), [Industrial orders & inventories](/thread/industrial-orders/), [Trade & external](/thread/trade-external/).

All macro indicators: /indicators/


## For LLMs & downloads

Markdown twin: /company/COO.md · JSON record: /company/COO.json · verified financials: /company/COO/financials.json / /company/COO/financials.csv · machine TOC for the whole site: /llms.txt